Literature DB >> 3428340

Pharmacokinetics of theophylline in hyperthyroid and hypothyroid patients with chronic obstructive pulmonary disease.

M Pokrajac1, D Simić, V M Varagić.   

Abstract

The pharmacokinetics of theophylline was investigated in five hyperthyroid, five hypothyroid, and five euthyroid patients, all with chronic obstructive pulmonary disease. Wide individual variability was found in theophylline kinetics, but the rate of elimination of theophylline was significantly higher in hyperthyroid, and lower in hypothyroid patients than in the euthyroid patients (kel = 0.155, 0.060 and 0.107 h-1, respectively). The values for clearance and volume of distribution were not consistently changed compared with those in the euthyroid group, although all the parameters except AUC were significantly different in hyperthyroid and hypothyroid patients. There was a positive correlation between both thyroxine and triiodothyronine serum concentrations and total body clearance of theophylline (r = 0.795 and r = 0.791, respectively). It is concluded that in spite of the wide interindividual variability and the relatively small differences in the pharmacokinetics of theophylline in thyroid dysfunction compared with the euthyroid status, these differences have to be considered in certain clinical situations, as they may require changes in the therapeutic regimen for administration of theophylline in hyperthyroid or hypothyroid patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428340     DOI: 10.1007/BF00544240

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Influence of thyroid status on plasma half-life of antipyrine in man.

Authors:  M Eichelbaum; G Bodem; R Gugler; D Schneider-Deters; H J Dengler
Journal:  N Engl J Med       Date:  1974-05-09       Impact factor: 91.245

2.  Proceedings: Changes in drug metabolizing ability in thyroid disease.

Authors:  J Crooks; A J Hedley; C Macnee; I H Stevenson
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

Review 3.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

4.  Theophylline: a remarkable window to the hepatic microsomal oxidases.

Authors:  J W Jenne
Journal:  Chest       Date:  1982-05       Impact factor: 9.410

5.  Increased clearance of propranolol in thyrotoxicosis.

Authors:  J Feely; I H Stevenson; J Crooks
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

6.  Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.

Authors:  E S Vesell; J R Shapiro; T Passananti; H Jorgensen; C A Shively
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

7.  Nonlinear theophylline elimination.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

8.  Life-threatening theophylline intoxication in a hypothyroid patient.

Authors:  D Aderka; G Shavit; D Garfinkel; M Santo; S Gitter; J Pinkhas
Journal:  Respiration       Date:  1983       Impact factor: 3.580

9.  Influence of thyroid function on theophylline kinetics.

Authors:  S Vozeh; M Otten; J J Staub; F Follath
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

10.  Plasma propranolol steady state concentrations in thyroid disorders.

Authors:  J Feely; J Crooks; I H Stevenson
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  1 in total

Review 1.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.